Preliminary Result in Patients with Primary Hepatoma Treated by Stereotactic Radiotherapy.
- Author:
Ki Mun KANG
1
;
Ihl Bohng CHOI
;
In Ah KIM
;
Byung Ock CHOI
;
Young Nam KANG
;
Gyu Young CHAI
;
Sung Tae HAN
;
Gyu Won CHUNG
Author Information
1. Department of Therapeutic Radiology, St. Mary's Hospital, The Catholic University of Korea, Seoul.
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Primary hepatoma;
Stereotactic radiotherapy
- MeSH:
alpha-Fetoproteins;
Carcinoma, Hepatocellular*;
Dyspepsia;
Female;
Fever;
Follow-Up Studies;
Humans;
Male;
Nausea;
Radiotherapy*;
Tomography, X-Ray Computed
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2001;19(1):34-39
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: It is not common to evaluate the response of the fractionated stereotactic radiotherapy (SRT) to primary hepatoma as compared with conventional radiotherapy. The purpose of the study was to take the preliminary result on the clinical trial of primary hepatoma by SRT. MATERIALS AND METHODS: From July 1999 to March 2000, thirty three patients were hospitalized in the St. Mary's Hospital, and treated with SRT for extracranial tumors. Among them, 13 patients were diagnosed to primary hepatoma and then applied by frameless SRT using 6 MV linac accelerator. There were 12 male and 1 female patients. They had the age of 44~66 year old (median : 59) and the tumor size of 10~825 cc (median : 185 cc). SRT was given to them 3~5 fractions a week (5 Gy/fraction, 90% isodose line) for 2~3 weeks. Median dose of SRT was 50 Gy and the range was 30~50 Gy. RESULTS: Follow-up period ranged from 3 months to 13 months with median of 8 months. After treating SRT to thirteen patients with primary hepatoma, the response of the tumor was examined by abdominal CT : they are classified by 1 complete regression (7.7%), 7 partial regression (53.8%), 4 minimal regression (30.8%), 1 stable disease (7.7%). The positive responses more than partial remission were 8 patients (61.5%) after the treatment. The level of serum alpha-fetoprotein (AFP) after the treatment as compared with pretreatment had been 92.3% decreased. There was no severe complication except dyspepsia 84.6%, mild nausea 69.2%, transient decreased of hepatic function 15.4% and fever 7.7%. CONCLUSION: SRT to the patients with primary hepatoma was potentially suggested to become the safe and more effective tool than the conventional radiotherapy even though there were relatively short duration of follow-up and small numbers to be tested.
